Table 1.
Baseline patient and tumor characteristics in sorafenib treated HCC patients with corresponding median overall survival (mOS, days), 95% confidence intervals (CI), and P values of the univariate analysis.
| Characteristic | No. (%) | mOS (days) |
95% CI | P value |
|---|---|---|---|---|
| Gender | ||||
| Male | 59 (78) | 150 | 112–188 | 0.207 |
| Female | 17 (22) | 209 | 185–233 | |
| Age (median years) | ||||
| >63 | 31 (41) | 176 | 112–239 | 0.799 |
| ≤63 | 45 (59) | 153 | 117–188 | |
| ECOG performance status | ||||
| 0-1 | 59 (77) | 186 | 57–170 | 0.005 |
| 2-3 | 16 (23) | 54 | 20–109 | |
| Child-Pugh Class | ||||
| A |
43 (57) |
191 | 168–214 | <0.001 |
| B |
29 (38) |
110 | 40–180 | |
| C | 4 (5) | 41 | 0–100 | |
| Portal vein thrombosis | ||||
| Present |
32 (42) |
198 | 120–232 | 0.967 |
| Absent | 35 (46) | 170 | 88–194 | |
| Unknown | 9 (12) | 217 | 138–174 | |
| Extrahepatic spread | ||||
| Present |
33 (43) |
137 | 81–193 | 0.211 |
| Absent |
42 (55) |
183 | 134–232 | |
| Ascites | ||||
| Present |
26 (34) |
161 | 134–188 | 0.633 |
| Absent |
50 (66) |
113 | 24–203 | |
| αFP level (ng/mL) | ||||
| ≥200 |
26 (34) |
160 | 110–210 | 0.016 |
| <200 | 56 (66) |
178 | 122–234 | |
| Serum albumin (g/L) | ||||
| ≥35 |
39 (51) |
186 | 169–203 | 0.003 |
| <35 | 36 (49) |
92 |
26–158 |
|
| Serum bilirubin (umol/L) | ||||
| ≥22 |
33 (43) |
98 | 36–160 | 0.005 |
| <22 | 43 (67) |
186 | 165–207 | |
| Serum lactatdehydrogenase LDH (U/L) | ||||
| ≥205 |
34 (50) |
150 | 83–217 | 0.136 |
| <205 | 34 (50) |
176 |
142–210 |
|
| Comorbidity* | ||||
| Presence of ≥1 substantial comorbidities |
58 (76) | 156 | 127–185 |
0.793 |
| No comorbidity |
18 (24) |
191 | 28–354 |
*Comorbidity assessed according to Charlson comorbidity classification.